Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. Because of the role of the kidney in many of the…
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…
Biologics in oncology, immunology, nephrology and endocrinology generated over $70 billion in 2015, nearly all attributed to branded biologics. As more branded agents lose patent protection and…
One of the most intriguing but administratively difficult trends in U.S. health insurers’ attempts to control the rising costs of prescription drugs is the use of outcomes-based contracting,…
Although the Alzheimer’s disease (AD) treatment paradigm is stable and most current treatments in the United States are generically available, several new therapies for AD, including the first…
Multiple Sclerosis | Emerging Therapies | Zinbryta | US is a three-wave series that tracks the introduction of Zinbryta for the treatment of multiple sclerosis (MS). The series is based on primary…
Schizophrenia is an often disabling psychiatric disease whose core treatment consists of years up to a lifetime of treatment with antipsychotics (older typical antipsychotics or newer atypical…
The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming societal burden. The AD population is poised to grow…
DRG’s Pharma Industry Report: Assessment and Rankings provides pharma executives with a comprehensive summary of the current and future state of the global pharmaceutical industry.
Multiple label expansions of premium-priced agents and the launch of four novel therapies will fuel the significant growth of the multiple myeloma market over the ten-year forecast period. The…
Until recently, SCCHN treatment lacked promising late-phase agents; the only targeted therapy approved for the indication was Bristol-Myers Squibb/Eli Lilly/Merck KGaA’s Erbitux. However, the…
Treatment of moderate to severe cancer pain will continue to be dominated by opioid analgesics for the foreseeable future. However, with the widespread epidemic of opioid abuse and misuse in the…
DRG anticipates the next ten years to be an exciting time in the hemophilia space, as the number of treatment options grow for patients with, and without, inhibitors. The hemophilia A pipeline is…
Muscular dystrophies (MDs) are a spectrum of genetic disorders characterized by muscle weakness that in severe disease forms can lead to loss of ambulation and early death. MDs share common…
Abstract Introduction: The Emerging Biosimilars Overview offers extensive coverage of the global biosimilar development landscape. We track over 350 currently available and novel biosimilar…